Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $135.18, with a high estimate of $155.00 and a low estimate of $110.00. Highlighting a 3.58% ...

The FDA has approved its requested updated versions of expanded warning labels for COVID-19 vaccines. As Healio previously ...

CVAC jumps 41% in a month after signing a $1.25B deal to be acquired by BioNTech to accelerate mRNA therapy development.

The updated guidance highlights myocarditis and pericarditis, two types of heart inflammation, as possible adverse events ...

Technological advances in the design and delivery of mRNA have catalysed the rapid development of mRNA COVID-19 vaccines by ...

U.S. health officials have expanded warnings about a rare heart side effect associated with the two leading COVID-19 vaccines ...

Detailed price information for Nektar Therapeutics (NKTR-Q) from The Globe and Mail including charting and trades.

As China's biotech sector matures, companies are striving to reconcile their bold innovation goals with a healthcare system ...

The Swedish-British pharma major AstraZeneca in partnership with the University of Oxford on Monday reported robust efficacy of up to 90% for the jointly ...

Moderna is suing Pfizer and BioNTech, accusing the companies of infringing on Moderna’s patents when they developed their own COVID-19 vaccine.

Norwegian software giant Visma has provisionally selected London over Amsterdam for its upcoming IPO, a rare win for the UK’s ...

The growing incidence of infectious diseases, cancer, and chronic illnesses has substantially increased the demand for ...